6CM
ORKA

683 Capital Management’s Oruka Therapeutics ORKA Stock Holding History

683 Capital Management’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-33,875
Closed -$657K – 248
2024
Q4 		$657K Buy
+33,875
New +$826K 0.04% 134

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

683 Capital Management's ORKA Position: Q1 2025 in Review

683 Capital Management sold out of Oruka Therapeutics (ORKA) in Q1 2025, closing a stake of 33,875 shares — an estimated $657K sold.

683 Capital Management first reported a position in ORKA in Q4 2024 and held it in 1 quarter. The position peaked at $657K in Q4 2024. 71 funds tracked by Wall St. Rank hold ORKA as of Q1 2025.

  • 683 Capital Management reported no remaining Oruka Therapeutics position as of Q1 2025 after selling out during the quarter.
  • 683 Capital Management sold 33,875 Oruka Therapeutics shares in Q1 2025, an estimated $657K.
  • 683 Capital Management first reported a position in Oruka Therapeutics in Q4 2024 and held it in 1 quarter.
  • 683 Capital Management's Oruka Therapeutics position peaked at $657K in Q4 2024.
  • 71 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2025.

Based on 683 Capital Management's 13F filing for Q1 2025, filed 15 May 2025.